{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:25:16Z","timestamp":1792182316291,"version":"4.4.0"},"reference-count":65,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2019,10,1]]},"DOI":"10.1001\/jamapsychiatry.2019.1702","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T15:01:34Z","timestamp":1564585294000},"page":"1052","source":"Crossref","is-referenced-by-count":158,"title":["Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics"],"prefix":"10.1001","volume":"76","author":[{"given":"Takahiro","family":"Masuda","sequence":"first","affiliation":[{"name":"Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York"},{"name":"Sumitomo Dainippon Pharma Co, Ltd, Medical Affairs, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuminari","family":"Misawa","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York"},{"name":"Yamanashi Prefectural KITA Hospital, Yamanashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Takase","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York"},{"name":"Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kane","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York"},{"name":"Department of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, New York"},{"name":"Feinstein Institute for Medical Research, Manhasset, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York"},{"name":"Department of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, New York"},{"name":"Feinstein Institute for Medical Research, Manhasset, New York"},{"name":"Department of Child and Adolescent Psychiatry, Charit\u00e9 Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"yoi190041r1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology.","volume":"174","author":"Howes","year":"2017","journal-title":"Am J Psychiatry"},{"issue":"3","key":"yoi190041r3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/15622970510030090","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia.","volume":"6","author":"Falkai","year":"2005","journal-title":"World J Biol Psychiatry"},{"key":"yoi190041r4","author":"Lehman","year":"2004"},{"issue":"5","key":"yoi190041r5","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0004867416641195","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders.","volume":"50","author":"Galletly","year":"2016","journal-title":"Aust N Z J Psychiatry"},{"issue":"9896","key":"yoi190041r6","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"yoi190041r7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamapsychiatry.2015.2955","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis.","volume":"73","author":"Samara","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"yoi190041r8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis.","volume":"209","author":"Siskind","year":"2016","journal-title":"Br J Psychiatry"},{"issue":"3","key":"yoi190041r9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jamapsychiatry.2015.2966","article-title":"The role of clozapine in treatment-resistant schizophrenia.","volume":"73","author":"Kane","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"yoi190041r10","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.jclinepi.2013.01.012","article-title":"Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry.","volume":"66","author":"Kane","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"yoi190041r11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/schbul\/sbs150","article-title":"Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.","volume":"40","author":"Kishimoto","year":"2014","journal-title":"Schizophr Bull"},{"issue":"10","key":"yoi190041r12","doi-asserted-by":"publisher","first-page":"957","DOI":"10.4088\/JCP.13r08440","article-title":"Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.","volume":"74","author":"Kishimoto","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"yoi190041r13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/schbul\/sbx090","article-title":"Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies.","volume":"44","author":"Kishimoto","year":"2018","journal-title":"Schizophr Bull"},{"issue":"15","key":"yoi190041r14","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of Observational Studies in Epidemiology: a proposal for reporting.","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"issue":"2","key":"yoi190041r19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"yoi190041r20","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale.","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"issue":"7109","key":"yoi190041r22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"yoi190041r23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot\u2013based method of testing and adjusting for publication bias in meta-analysis.","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"issue":"3","key":"yoi190041r24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"1","key":"yoi190041r25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results.","volume":"59","author":"Furukawa","year":"2006","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"yoi190041r26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1590\/S1516-44462007000300004","article-title":"Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine.","volume":"29","author":"Castro","year":"2007","journal-title":"Braz J Psychiatry"},{"issue":"6","key":"yoi190041r27","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1176\/ajp.156.6.863","article-title":"Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine.","volume":"156","author":"Conley","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"3","key":"yoi190041r28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.psychres.2011.04.004","article-title":"Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine.","volume":"188","author":"Werneck","year":"2011","journal-title":"Psychiatry Res"},{"issue":"11","key":"yoi190041r29","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.euroneuro.2013.02.003","article-title":"Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary.","volume":"23","author":"Bitter","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"yoi190041r30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1176\/appi.ps.201300085","article-title":"Outcomes of Medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations.","volume":"66","author":"Velligan","year":"2015","journal-title":"Psychiatr Serv"},{"issue":"2","key":"yoi190041r31","first-page":"67","article-title":"Effectiveness of clozapine use in delaying hospitalization in routine clinical practice: a 2 year observational study.","volume":"43","author":"Nyakyoma","year":"2010","journal-title":"Psychopharmacol Bull"},{"issue":"4","key":"yoi190041r32","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.pnpbp.2008.01.009","article-title":"Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia.","volume":"32","author":"Kim","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"yoi190041r33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/10401230309085667","article-title":"Rehospitalization risk with second-generation and depot antipsychotics.","volume":"15","author":"Conley","year":"2003","journal-title":"Ann Clin Psychiatry"},{"issue":"3","key":"yoi190041r34","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/pds.v23.3","article-title":"Mortality, attempted suicide, re-hospitalisation and prescription refill for clozapine and other antipsychotics in Sweden: a register-based study.","volume":"23","author":"Ringb\u00e4ck Weitoft","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"yoi190041r35","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1176\/appi.ajp.2015.15030332","article-title":"Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia.","volume":"173","author":"Stroup","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"7561","key":"yoi190041r36","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1136\/bmj.38881.382755.2F","article-title":"Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study.","volume":"333","author":"Tiihonen","year":"2006","journal-title":"BMJ"},{"issue":"4","key":"yoi190041r37","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00213-011-2242-3","article-title":"Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study.","volume":"216","author":"Guo","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"yoi190041r38","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S1726-4901(09)70254-0","article-title":"Comparison of time to rehospitalization among schizophrenic patients discharged on typical antipsychotics, clozapine or risperidone.","volume":"69","author":"Lin","year":"2006","journal-title":"J Chin Med Assoc"},{"issue":"5","key":"yoi190041r39","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/acps.2016.134.issue-5","article-title":"Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study.","volume":"134","author":"Vanasse","year":"2016","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"yoi190041r40","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3325\/cmj.2008.2.215","article-title":"Two-year rehospitalization rates of patients with newly diagnosed or chronic schizophrenia on atypical or typical antipsychotic drugs: retrospective cohort study.","volume":"49","author":"Herceg","year":"2008","journal-title":"Croat Med J"},{"key":"yoi190041r41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/POR","article-title":"Schizophrenia Outpatient Health Outcomes study: twelve-month findings.","volume":"3","author":"Novick","year":"2012","journal-title":"Pragmat Obs Res"},{"issue":"430","key":"yoi190041r42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-0447.2006.00757.x","article-title":"Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia.","author":"Williams","year":"2006","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"2","key":"yoi190041r43","doi-asserted-by":"publisher","first-page":"240","DOI":"10.4088\/JCP.v69n0210","article-title":"Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study.","volume":"69","author":"Taylor","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"yoi190041r44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0920-9964(02)00231-1","article-title":"Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone.","volume":"60","author":"Green","year":"2003","journal-title":"Schizophr Res"},{"issue":"6","key":"yoi190041r45","doi-asserted-by":"publisher","first-page":"818","DOI":"10.4088\/JCP.v68n0601","article-title":"Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia.","volume":"68","author":"Cooper","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"yoi190041r46","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/PPA","article-title":"Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia.","volume":"2","author":"Ascher-Svanum","year":"2008","journal-title":"Patient Prefer Adherence"},{"issue":"3-4","key":"yoi190041r47","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s00213-003-1506-y","article-title":"Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.","volume":"169","author":"Sharma","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"yoi190041r48","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/(ISSN)1099-1077","article-title":"The use of atypical antipsychotics in the treatment of schizophrenia in North Staffordshire.","volume":"20","author":"Hodgson","year":"2005","journal-title":"Hum Psychopharmacol"},{"issue":"4","key":"yoi190041r49","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.euroneuro.2006.09.005","article-title":"Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results.","volume":"17","author":"Haro","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"yoi190041r50","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/hup.2542","article-title":"Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia.","volume":"31","author":"Buoli","year":"2016","journal-title":"Hum Psychopharmacol"},{"issue":"6","key":"yoi190041r51","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/ijcp.2010.64.issue-6","article-title":"Factors associated with achieving minimally symptomatic status by patients with schizophrenia: results from the 3-year intercontinental Schizophrenia Outpatients Health Outcomes study [published correction appears in Int J Clin Pract. 2010;64(10):1459].","volume":"64","author":"Treuer","year":"2010","journal-title":"Int J Clin Pract"},{"issue":"9","key":"yoi190041r52","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1185\/03007990903102966","article-title":"Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia.","volume":"25","author":"Karagianis","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"yoi190041r53","doi-asserted-by":"publisher","first-page":"521","DOI":"10.4088\/JCP.v59n1005","article-title":"Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study.","volume":"59","author":"Lindenmayer","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"yoi190041r54","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/acps.2017.135.issue-4","article-title":"The impact of clozapine on hospital use: a systematic review and meta-analysis.","volume":"135","author":"Land","year":"2017","journal-title":"Acta Psychiatr Scand"},{"issue":"11","key":"yoi190041r55","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1177\/0706743717718167","article-title":"Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis.","volume":"62","author":"Siskind","year":"2017","journal-title":"Can J Psychiatry"},{"issue":"6","key":"yoi190041r56","doi-asserted-by":"publisher","first-page":"603","DOI":"10.4088\/JCP.12r08064","article-title":"Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?","volume":"74","author":"Nielsen","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"yoi190041r57","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"yoi190041r58","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.molmed.2010.10.010","article-title":"Antipsychotic drugs and obesity.","volume":"17","author":"Correll","year":"2011","journal-title":"Trends Mol Med"},{"issue":"2","key":"yoi190041r59","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/wps.v14.2","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"issue":"3","key":"yoi190041r60","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis.","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatry"},{"issue":"2","key":"yoi190041r61","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/wps.20309","article-title":"Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis.","volume":"15","author":"Vancampfort","year":"2016","journal-title":"World Psychiatry"},{"issue":"9690","key":"yoi190041r62","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-Year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet"},{"key":"yoi190041r63","first-page":"S0920-9964(17)30762-4","article-title":"Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia.","author":"Taipale","year":"2017","journal-title":"Schizophr Res"},{"issue":"3","key":"yoi190041r64","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/schbul\/sbu164","article-title":"Antipsychotic treatment and mortality in schizophrenia.","volume":"41","author":"Torniainen","year":"2015","journal-title":"Schizophr Bull"},{"key":"yoi190041r65","doi-asserted-by":"crossref","DOI":"10.1093\/schbul\/sby015.215","article-title":"Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years.","author":"Vermeulen","year":"2018","journal-title":"Schizophr Bull"},{"key":"yoi190041r21"},{"key":"yoi190041r2","unstructured":"National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. Clinical Guideline CG178. https:\/\/www.nice.org.uk\/guidance\/cg178. Published February 2014. Updated March 2014. Accessed August 12, 2017."},{"key":"yoi190041r15","unstructured":"WellsGA, SheaB, O\u2019ConnellD, . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed August 12, 2017."},{"key":"yoi190041r16","unstructured":"Google Translate. https:\/\/translate.google.com. Accessed May 22, 2017."},{"key":"yoi190041r17","unstructured":"WebPlotDigitizer. https:\/\/automeris.io\/WebPlotDigitizer\/. Accessed May 22, 2017."},{"key":"yoi190041r18","unstructured":"HigginsJPT, GreenS, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. http:\/\/handbook-5-1.cochrane.org\/. Updated March 2011. Accessed August 12, 2017."}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2738765\/jamapsychiatry_masuda_2019_oi_190041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T15:00:43Z","timestamp":1570028443000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2738765"}},"subtitle":["A Systematic Review and Meta-analysis of Cohort Studies"],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.1702","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,1]]}}}